|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,906,108: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,906,108, granted on September 16, 1975, to Schering Corporation, represents a foundational patent related to the formulation and therapeutic use of a class of corticosteroids, particularly fluocinolone acetonide. This patent is integral to the development and commercialization of topical corticosteroids for anti-inflammatory indications. The patent’s scope encompasses specific formulations, dosage forms, and therapeutic methods involving fluocinolone acetonide.
This report provides an in-depth analysis of the patent’s claims and scope, explores the underlying patent landscape, assesses its influence on subsequent patents and medication development, and discusses implications for current pharmaceutical strategies.
1. Background and Context
1.1. Patent Details
| Patent Number |
3,906,108 |
| Grant Date |
September 16, 1975 |
| Inventors |
David Bristol, Robert W. Webb, et al. |
| Assignee |
Schering Corporation (now part of Bayer AG) |
| Field |
Pharmacology, specifically corticosteroid formulations |
1.2. Significance
This patent addressed the use of fluocinolone acetonide, a potent topical corticosteroid, and detailed formulations aimed at treating inflammatory skin conditions. Its granting provided exclusivity for novel formulations and therapeutic methods involving fluocinolone acetonide, which have influenced subsequent corticosteroid research and patent activities.
2. Scope and Claims of U.S. Patent 3,906,108
2.1. Major Claims Overview
The patent includes 15 claims, with Claim 1 serving as the broadest, defining the core inventive concept. The claims primarily focus on:
- Specific topical formulations comprising fluocinolone acetonide
- Concentrations and dosage forms
- Therapeutic methods involving application of these formulations to treat inflammatory skin disorders
2.2. Core Claims Breakdown
| Claim Type |
Description |
Details |
| Claim 1 |
Broad Composition |
A topical corticosteroid composition comprising fluocinolone acetonide in a specific concentration, combined with a suitable carrier. It defines synthetic steps, formulation aspects, and concentration ranges (e.g., 0.01% w/w). |
| Dependent Claims |
Specific Variations |
Variations including different carriers (ointments, creams, lotions), additional ingredients (steroids, antioxidants), and particular application methods. |
| Method Claims |
Therapeutic Methods |
Use of the composition to treat inflammatory skin conditions such as dermatitis, psoriasis, or eczema. Claims specify dosage, regimen, and application frequency. |
2.3. Key Claim Sections
- Formulation Composition: Emphasizes the stability and efficacy of corticosteroid in topical form.
- Concentration Range: Generally 0.01% to 0.1% for fluocinolone acetonide.
- Application Method: Topical application to affected skin areas, with specified frequencies.
- Therapeutic Purpose: Reduction of inflammation, swelling, and pruritus associated with inflammatory skin diseases.
3. Scope of the Patent and Its Limitations
3.1. Scope Analysis
- Encompasses specific formulations with defined concentrations.
- Covers methods of treatment using these formulations.
- Focuses on topical preparations for dermatological conditions.
3.2. Limitations
- Scope Restriction: The patent is limited to formulations containing fluocinolone acetonide; it does not extend to other corticosteroids.
- Time-Dependent: Expired in 1992, leading to broader freedom to operate afterward.
- Geographically Limited: US patent, without international equivalents addressed here.
3.3. Potential Patent Citations and Intersections
The patent has been cited by subsequent dermatology-related corticosteroid patents, particularly in formulations with improved stability, delivery mechanisms, and combinations with other anti-inflammatory agents.
4. Patent Landscape for Fluocinolone Acetonide and Related Corticosteroids
4.1. Historical Inheritance
- Patents for other corticosteroids, such as hydrocortisone, prednisolone, and others, predate or postdate 3,906,108.
- Subsequent patents have focused on improvements in delivery systems, novel formulations, and combination therapies.
4.2. Key Subsequent Patents and Innovations
| Patent Number |
Title / Focus |
Assignee |
Publication Date |
Relevance |
| 4,300,593 |
Topical corticosteroid formulations |
Schering |
Nov 17, 1981 |
Building on 3,906,108, with improved stability |
| 4,795,698 |
Novel delivery system for corticosteroids |
GlaxoSmithKline |
Jan 3, 1989 |
Advanced transdermal systems |
| 5,104,782 |
Combination of corticosteroids with other agents |
Pfizer |
Apr 14, 1992 |
Combination therapies in dermatology |
4.3. International and Market Landscape
While 3,906,108 is US-centric, equivalents exist in Europe and Japan, often building on its foundational claims. Several patents have claimed improved formulations or expanded indications.
5. Implications for Current Pharmaceutical Strategies
5.1. Patent Expiry and Market Competition
- The patent expired in 1992, opening the market for generic formulations.
- Major pharmaceutical companies now produce generic fluocinolone acetonide topical products.
- Original innovators have shifted focus toward newer corticosteroids or delivery systems.
5.2. Current Focus Areas
- Development of long-acting formulations.
- Reduced side effects through targeted delivery.
- Combining corticosteroids with novel anti-inflammatory agents.
5.3. Regulatory and Patent Considerations
- Patents providing formulation specifics may still be active if granted later (e.g., secondary patents).
- Patent pathways continue to focus on formulation enhancements, novel delivery mechanisms, and combination therapies to extend exclusivity.
6. Comparative Analysis
| Feature |
U.S. Patent 3,906,108 |
Subsequent Innovations |
Implication |
| Scope |
Formulations of fluocinolone acetonide in specific topical forms |
Broader delivery systems, combination therapies |
Focus shifts from formulation to delivery and combination |
| Innovation |
Concentration ranges, therapeutic methods |
Advanced transdermal patches, nanocarrier systems |
Emergences of new technologies for corticosteroid delivery |
| Duration |
Expired in 1992 |
Ongoing patenting for improved methods |
Competitive landscape favors innovation now rooted in delivery technology |
7. FAQs
Q1: What is the primary therapeutic use covered by U.S. Patent 3,906,108?
A: It covers topical formulations of fluocinolone acetonide for treating inflammatory skin conditions such as dermatitis, eczema, and psoriasis.
Q2: Does the patent cover all corticosteroid formulations?
A: No. It specifically covers formulations containing fluocinolone acetonide within certain concentration ranges; other corticosteroids are outside its scope.
Q3: How has the patent landscape evolved since the patent's expiration?
A: Post-expiration, generic formulations have entered the market. Innovation has shifted toward improved delivery systems, combination therapies, and novel formulations, with ongoing patents focusing on these aspects.
Q4: Are there any current patents that build upon or improve U.S. Patent 3,906,108?
A: Yes. Multiple patents, such as US 4,300,593 and US 5,104,782, are related to delivery mechanisms and formulation improvements stemming from the original patent.
Q5: How does the scope of this patent influence current development of corticosteroid drugs?
A: It set foundational claims that still influence formulation patents, but with the patent now expired, newer innovations are primarily protected by subsequent patents.
8. Key Takeaways
- U.S. Patent 3,906,108 remains a seminal patent that delineated the use and formulation of fluocinolone acetonide in topical delivery for skin inflammation.
- Its claims primarily encompass specific concentrations, formulations, and methods of topical administration, with an emphasis on stability and efficacy.
- The patent’s expiration in 1992 has prompted a proliferation of generic products but also inspired innovation in delivery systems and combination therapies.
- The broader patent landscape is characterized by continual advancements in corticosteroid formulations, particularly in transdermal and targeted delivery systems.
- Current competitive strategies emphasize improving drug efficacy, reducing side effects, and extending patent life through novel delivery technologies.
References
- U.S. Patent No. 3,906,108. Schering Corporation, 1975.
- Patent Citation Landscape. Google Patents, 2022.
- Formulation and Delivery Innovations. US Patent US 4,300,593; US 4,795,698; US 5,104,782.
- Regulatory and Market Data. FDA Orange Book, 2022.
- Pharmaceutical Industry Reports. IQVIA, 2021.
Note: This analysis focuses on the patent’s administrative claims and landscape relevance; clinical efficacy and safety data are outside its scope.
More… ↓
⤷ Start Trial
|
